Premium
Effect of cisapride on gastroesophageal reflux in children with chronic bronchopulmonary disease: A double‐blind cross‐over pH‐monitoring study
Author(s) -
Saye Zimbu N.,
Forget Pierre Ph.,
Geubelle Fernand
Publication year - 1987
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.1950030105
Subject(s) - cisapride , medicine , reflux , placebo , prokinetic agent , gastroenterology , esophageal disease , anesthesia , esophagus , disease , alternative medicine , pathology
Fourteen patients with chronic bronchopulmonary disease and suspected of having gastroesophageal reflux were studied for 16 hr by intraesophageal pH monitoring to investigate the effect of the prokinetic drug cisapride. Cisapride was administered orally in a double‐blind cross‐over study. The initial dose was 0.3 mg/kg, followed by 0.15 mg/kg every 4 hr for 12 hr. Cisapride was shown to be superior to placebo in reducing gastroesophageal reflux. Both during the total recording period and during the sleep period, cisapride significantly decreased the percentage of time during which the pH was 4 or less (vs placebo; total period, −60%; sleep, −80%) and reduced the number of reflux spells of at least 5 min (−64%; −92%). No adverse effects of cisapride were observed. Pediatr Pulmonol 1987; 3:8–12 .